Fri, Jul 25, 2014, 1:37 PM EDT - U.S. Markets close in 2 hrs 23 mins

Recent

% | $
Click the to save as a favorite.

Isis Pharmaceuticals, Inc. Message Board

  • rubiconsf rubiconsf Sep 29, 2005 2:50 PM Flag

    Yo Ho Ho

    Isis Pharmaceuticals' drug development program is making headway. ISIS 301012, for high cholesterol, is set to begin Phase II testing within the next few months. ISIS 113715, for type 2 diabetes, is also showing promise, as favorable data has, so far, been reported in a Phase II trial. The drug will continue to undergo Phase II studies through yearend.

    Meanwhile, partner-driven research is expanding, auguring well for revenues. Notably, a four-year collaboration with Eli Lilly to develop oncology drugs was recently extended by about two years. Isis also entered into a multiyear collaboration with Pfizer, valued at up to $80 million, to develop treatments for ophthalmic diseases. We're also upbeat about an RNA-based collaboration between Alnylam and a major drugmaker that's in the works, which will use Isis' technology licensed to Alnylam. This ought to translate into milestone and royalty payments for Isis.

    The TIGER Biosensor System is being commercialized. Isis has won several government contracts that provide funding for the development of additional applications of the system (designed by Isis' Ibis unit to detect infectious diseases). The system is mainly intended for government use in biowarfare defense and for non-government customers (such as hospitals) for disease control. Once commercialized, TIGER may well become a meaningful source of revenues.

    Isis has strengthened its balance sheet, converting a $100 million interest-free loan from Eli Lilly into 2.5 million shares of stock. It also raised $48 million through an equity offering of 12 million shares. Given the proceeds raised and a lower cash-burn rate (thanks to recent restructuring efforts), there should be sufficient cash on hand to support R&D activities at least into 2007.

    Still, this stock is risky. Despite our belief that profitability may be achieved by late decade, the stock's price tends to swing widely, as it is largely based on R&D-related news.

    J. Susan Ferrara September 23, 2005

    3 to 5 Year Projections*


    Price Gain Ann'l Tot. Return
    High 10 100% 19.0%
    Low 5 NMF NMF

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Good homework, Susan.

      But Isis, like human evolution, is not an highway.

      Often we take a jump, instead of a step.

      This stock will jump very up, in late October, or early November, over $ 6,00, than $ 7,00.

      Thenmore jumps up, on Dec, Jan. and all February, the month we will fly ove $ 10,00.

      Just my opinion.

    • Start this and start that phase 1 and 2 galores for 15 years. You can forget about a large scale phase 3 successful 2nd generation trial with Isis antisense. Just thought that I would bring you up to speed.

      Geez, you people are getting more desperate every day. :>(

 
ISIS
30.03-0.59(-1.93%)1:36 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.